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27 setting meeting organized by COST Action IS1303 “Citizen’s
28 Health through public-private Initiatives: Public health, Market
29 and Ethical perspectives,” participants discussed the main chal-
30 lenges associated with the expanded availability of genomic
31 information, with a specific focus on public-private partner-
32 ships, and provided an outline from which to discuss in detail
33 the identified challenges. This paper summarizes the points
34 raised at this meeting in five main parts and highlights the
35 key cross-cutting themes. In light of the increasing availability
36 of genomic information, it is expected that this paper will pro-
37 vide timely direction for future research and policy making in
38 this area.
39 Keywords Genomics . Clinical and research genomic data .
40 Return of results . Data sharing . Informed consent .
41 Direct-to-consumer genetic testing
42 IntroductionQ3
43 Rapid advances in microarray and sequencing technologies
44 are making genotyping and genome sequencing more afford-
45 able and readily available. The decreasing cost and time need-
46 ed for sequencing has generated the expectation that the use of
47 next-generation sequencing technologies (NGS) (i.e., new
48 high-throughput and massively parallel DNA-sequencing
49 technologies) will greatly increase in a wide range of contexts
50 (Rehm 2017). Already, NGS is increasingly used to identify
51 causative mutations in some patients with rare or undiagnosed
52 diseases of genetic origin (Levenson 2014). Furthermore, the
53 expectation has grown that genomic-sequencing technologies
54 could be applied in a broad range of clinical situations, leading
55 to personalized diagnoses and personalized drug therapy. Data
56 arising from genome sequencing is likely to lead to a better
57 prediction of disease risk and treatment response and the
58 avoidance of adverse events (Lazaridis et al. 2016; Rehm
59 2017; Soden et al. 2014; van Zelst-Stams et al. 2014).
60 Furthermore, it is anticipated that an increasing number of
61 healthy individuals will use genomic technologies to predict
62 personal risks (Knoppers et al. 2014; van El et al. 2013). For
63 over a decade now, genetic testing companies have been mar-
64 keting and selling genetic tests direct to consumer (DTC) via
65 the internet (Howard and Borry 2012). A number of online
66 interpretation services (such as Promethease, LiveWello, and
67 Interpretome) have also emerged that allow consumers to re-
68 ceive an analysis of their own raw genomic data received from
69 these DTC genetic testing companies. These online services
70 will allow for further interpretation of the user’s genome.
71 Between 2013 and 2017, the COST Action IS1303
72 “Citizen’s Health through public-private Initiatives: Public
73 health, Market and Ethical perspectives” identified and
74 reunited a community of academic and industry researchers
75 as well as other stakeholders with expertise in bioethics, social
76studies of science and technology, genetics, information and
77communication technology, stakeholder deliberation, and
78patient-centered initiatives (PCI). As part of this networking
79project, a meeting was convened in Leuven (Belgium) on 21
80and 22 March 2016, in order to identify and discuss the chal-
81lenges related to the expanded availability of genomic infor-
82mation in society. A particular focus was placed on the context
83of public-private partnerships in genomics. The meeting
84aimed to promote a mutually informative and collaborative
85agenda-setting process. The aim of this document is to iden-
86tify, via horizon scanning, the main forthcoming challenges
87and areas of interest arising from the availability of genomic
88information in society. It is expected that the results of this
89paper will allow for constructive reflection on future develop-
90ments and the identification of research priorities. It is de-
91signed for use by a wide array of stakeholders, such as regu-
92lators, policy makers, healthcare institutions, patient organiza-
93tions, and industry.
94Current Q4and future challenges were identified in the context
95of five salient/key relationships in the realm of genetics and
96genomics (Fig. 1): (1) healthcare professionals, patients, and
97families; (2) genomic data and its impact on individuals and
98families; (3) researchers, research participants, and the general
99public; (4) genomics, society, and its values; and (5) industry,
100governments, and citizens. An overlap between these different
101relationships obviously exists, but they help to frame the var-
102ious areas of focus. As well as these overlaps, some identified
103challenges are also relevant to more than one type of
104relationship.
105Healthcare professionals, patients, and families
106Developing policies for reporting results The clinical imple-
107mentation of NGS technologies creates huge challenges for
108laboratories and clinicians at the level of returning results. The
109use of NGS for whole exome or whole genome sequencing
110has the potential to identify variants in genes for which the
111function is unknown or variants for which the pathogenicity
112has not been established (Ream andMikati 2014). Some com-
113mentators have concluded that using NGS may “raise more
114questions than it answers for some patients” (Ream andMikati
1152014). In addition to issues related to the interpretation and
116reporting of these variants of unknown significance (VUS),
117uncertainty remains regarding how to deal with incidental
118findings unrelated to the clinical indication of the test. This
119issue is particularly complicated when the variants relate to
120late-onset conditions (Katsanis and Katsanis 2013) or
121untreatable conditions (Vasta et al. 2012). Such information
122can also have familial implications (Babkina and Graham
1232014). Different guidelines and protocols that describe how
124to handle the return of results, including and also VUS and
125incidental findings have been developed and need further
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126 elaboration as well as potential harmonization, especially with
127 regard to the pertinent responsibilities of involved parties
128 (Vears et al. 2017a, b).
129 Developing appropriate clinical and counseling frame-
130 works and structures The enhanced technical options for
131 genetic testing are not yet accompanied by comprehensive
132 genetic counseling models for the genomic era. New models
133 and frameworks of genetic counseling that extend beyond the
134 traditional clinical genetics and genetic counseling setting
135 need to be developed (Bradbury et al. 2014). Given the poten-
136 tial of NGS to generate high volumes of data, and uncer-
137 tainties around results of the data generated, there is a pressing
138 need to revitalize current genetic counseling services.
139 Furthermore, individuals receiving sequencing results may
140 adopt different roles such as patient, customer, hobbyist, or
141 activist. Previously, individuals largely had a unique and de-
142 fined pathway for accessing genetic information through the
143 traditional healthcare setting (via clinical geneticists and/or
144 genetic counselors) on the basis of specific clinical concerns
145 or family history. In contrast, individuals now have the
146opportunity to choose genetic testing without the intermediary
147of a professional assessment of clinical need and can obtain
148testing for a variety of purposes, including mere curiosity.
149Individuals may also choose to use sequencing services that
150provide access to raw data without interpretation, providing
151them with “unfiltered” genetic information to use as they see
152fit. They could, for example, attempt to “self-interpret” with
153the support of publicly available sites for the analysis of ge-
154netic data (such as openSNP), or use it for entirely unrelated
155purposes such as artistic endeavors (Werner-Felmayer 2014).
156Genetic counseling policies should be developed in relation to
157the different ways individuals can access genomic informa-
158tion. As a part of this, it is important to (re)define the roles of
159clinical geneticists, genetic/genomic counselors, and other
160professionals such as general practitioners specialized in clin-
161ical genetics who provide advice in relation to the wide array
162of genomic information (Middleton et al. 2015).
163Training healthcare professionals so they understand ge-
164nomics and its role in healthcare In the clinical setting, even
165among genetic experts, there is a clear need for a collaborative,
Cross-cutting themes
1. Keeping trust
2. Building evidence
3. Transferring 
knowledge to 
stakeholders
4. Ensuring data 
security
Health care professionals, 
patients and families
1. Developing policies around 
reporting of results
2. Developing appropriate clinical 
and counselling frameworks and 
structures
3. Training healthcare rofessionals 
so they understand genomics and 
its role in healthcare. 
4. Identifying the ethical and legal 
responsibilities of healthcare 
professionals
Industry, governments 
and citizens
1. Balancing public and 
private interests
2. Defining appropriate 
policies with regard to 
direct-to-consumer genetic 
testing
Genomics, society and 
its values
1. Minimizing and avoiding 
negative disruptive uses and 
impact of genetic 
information. 
2. Equity and fairness in 
service provision and access 
to benefits 
of genomic technologies
3. Concerns regarding 
linking genomic data to other 
data sources 
Researchers, research 
participants, and the general 
public
1. Enabling data sharing while 
respecting ethical safeguards 
2. Adapting oversight and 
governance mechanisms of 
research
3. Assessing innovations in 
research participation
4. Assessing innovations at the 
level of informed consent
The impact of genomic data on
individuals and families
1. Identify strategies for 
offering appropriate informed 
choices to patients
2. Identify strategies to 
improve interfamilial genetic 
communication
3. Understand the impact of 
genomic information on the 
individual identity
Fig. 1 Five salient/key
relationships in the realm of
genetics and genomics and the
central cross-cutting themes
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166 multidisciplinary effort (biology, bioinformatics, clinical ge-
167 netics) to interpret and understand NGS results. As genomics
168 continues to move from specialized centers to mainstream
169 medicine, various medical specialists who are unfamiliar with
170 clinical genetics or genetic counseling may be increasingly
171 required to have a greater role in the prescribing and/or inter-
172 pretation of genetic testing and the communication of geno-
173 mic information. For instance, Gen-Equip (Paneque et al.
174 2017; Primary Care Genetics) is an example of an effort that
175 has beenmade to enable health professionals who are working
176 in primary care to update their knowledge and skills in genet-
177 ics. The Gen-Equip project (https://www.primarycaregenetics.
178 org) was co-funded by the EU Erasmus+ Programme. It de-
179 veloped a program of online learning modules and tools to
180 support daily practice in primary care about genetics.
181 It will be necessary to educate and train healthcare profes-
182 sionals to translate this changing landscape into appropriate
183 patient care, including family centered. Authors have identi-
184 fied a need for a new kind of physician who will be trained in
185 several disciplines including medicine, genetics, and counsel-
186 ing (Gonzalez-Garay et al. 2013; Iacobazzi et al. 2014). Others
187 advocate either for clinical geneticists to have a more promi-
188 nent role in the clinical interpretation of data (Gomez-Lobo
189 2014; Grody et al. 2013) or for several experts such as “mo-
190 lecular biologists, clinical geneticists, and bioinformaticists”
191 to combine their efforts for data interpretation (Grody et al.
192 2013). The implementation of NGS is no longer viewed as an
193 individual physician’s endeavor, and therefore clinics offering
194 genomic testing will need to adapt to this increased need for
195 cross-disciplinary collaboration (Rigter et al. 2013), including
196 conducting ethical, legal, and social issues research to accom-
197 pany the clinical advances, especially while roles for labora-
198 tory geneticists and clinicians are changing.
199 Identifying the ethical and legal responsibilities of
200 healthcare professionals towards families Healthcare pro-
201 fessionals are increasingly asked for advice about the commu-
202 nication of genetic risk information to individuals as well as
203 regarding communication within families. Based on the pre-
204 mise of medical confidentiality, professional guidelines rec-
205 ommend that professionals should not contact a client’s family
206 members directly (Forrest et al. 2007) without his or her ap-
207 proval. Adherence to this guideline means that the client’s
208 wish to disclose (or not disclose) information to relatives,
209 must be respected (Hodgson and Gaff 2013). However, these
210 guidelines also state that professionals should actively encour-
211 age clients to transmit relevant risk information to relatives
212 and support them throughout the communication process
213 (Forrest et al. 2007). When clients fail to disclose important
214 information to relatives, professionals are confronted with po-
215 tential ethical tensions between, on the one hand, addressing
216 the needs of the individual and his/her right to confidentiality,
217 and on the other hand, considering the potential for harm to
218uninformed relatives (Dheensa et al. 2015a). Some have rec-
219ommended a more proactive role for health professionals
220(Battistuzzi et al. 2012; Otlowski 2013), although there is lack
221of clarity regarding how this could be achieved. Legislative
222frameworks in countries such as France, Australia, and
223Norway have created mechanisms that provide healthcare pro-
224fessionals with the potential to override their patients’ confi-
225dentiality in the interests of their relatives (Dheensa et al.
2262015b; D’Audiffret van Haecke and de Montgolfier 2016;
227Weaver 2016). It is important to study the impact of these
228legislative changes and to consider whether they should be
229implemented more widely. The fact that such large volumes
230of data can be generated about patients also raises the question
231of whether there is a duty for health professionals to re-contact
232former patients should new genomic findings of potential clin-
233ical relevance come to light (Carrieri et al. 2017b). Although
234disclosing these findings may offer novel and more effective
235diagnostic/clinical options to the patient, re-contact also has
236the potential to cause anxiety and alarm to recipients of this
237new information, and their families, and may be logistically
238very difficult to achieve in practice. This highlights the need to
239explore the attitudes of individuals regarding communication
240of risks to their families as well as the factors that influence
241them towards a course of action. This also raises questions
242about the level of confidence of health professionals in
243performing the proposed practices, the provision of necessary
244funding and resources for these activities, as well as the crea-
245tion of the necessary infrastructure to accommodate said prac-
246tices. This might include updated registries, patient portals,
247other forms of consent, mobilization of patients’ associations
248in order to sensitize patients to regularly contacting genetic
249services, providing ongoing training for the genetic counsel-
250ing workforce, and being open to adopting novel approaches
251if needed (Carrieri et al. 2017a).
252The impact of genomic data on individuals
253and families
254Identifying strategies for offering appropriate, informed
255choices to patients In light of the new potential applications
256arising from using NGS in healthcare, various challenges re-
257main with regard to obtaining informed consent, the reporting
258of results, and the inclusion of patient preferences regarding
259the return of results (Budin-Ljøsne et al. 2016). Determining
260which results should be returned, including incidental findings
261and VUS, following the use NGS for diagnostic purposes
262poses challenges for laboratories and clinicians (see below).
263It also poses challenges for individuals and families in making
264(truly) informed decisions with regard to the results they wish
265to receive. Indeed, they may not have enough information
266and/or understanding to support such a truly informed deci-
267sion. More research is required to develop appropriate
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268 strategies to explain the different types of results that could be
269 generated, and the related uncertainties before a test. Research
270 also needs to be performed regarding how best to report results
271 to patients, including how to support probands to discuss,
272 these results with family members (Daly et al. 2016; de
273 Geus et al. 2016), if necessary. This approach should include
274 discussion among different stakeholders, as well as careful
275 consideration of the impact that reporting strategies could cre-
276 ate in both patient populations and the general public, and with
277 regard to the potential costs to the healthcare system. The
278 access to genomic medicine will also increasingly be available
279 throughout the lifespan, from conception to elderly care.
280 Individuals will be confronted with increasing technological
281 possibilities and related informed choices to be made in vari-
282 ous types to situations, such as preconceptional carrier screen-
283 ing, prenatal testing, preimplantation genetic diagnosis, new-
284 born screening, tumor profiling, or genomic risk assessments
285 in adult life (Rehm 2017).
286 Identifying strategies to support interfamilial genetic com-
287 municationClinical genetic healthcare providers have always
288 strongly emphasized the familial nature of genetic informa-
289 tion, and this has, in turn, guided patients’ use of these genetic
290 services. Emphasis has mainly been placed on helping the
291 individual understand testing, obtaining consent, and
292 returning the results of testing to the individual. Less attention
293 has been given to how to help these individuals respond to
294 their genetic information, particularly when considering the
295 shared nature of genetic information. As genetic sequencing
296 and testing also has implications for relatives, genetic
297 healthcare services have the challenge of supporting families,
298 not just individuals (Eisler et al. 2017). Sequencing whole
299 genomes/exomes potentially increases the need to involve
300 family members to clarify inconclusive test results (newly-
301 discovered variants and variants of unknown significance)
302 (Hallowell et al. 2015). Therefore, more research is required
303 to explore the following: how families cope with genetic in-
304 formation; to what extent barriers exist relating to the disclo-
305 sure of genetic information within families; and how such
306 information impacts interfamilial relations. Although patients
307 might initially feel inclined to transmit genetic risk informa-
308 tion to their relatives, in reality, sharing of this information can
309 be problematic. Individual perspectives, patterns of family
310 dynamics, disease characteristics, and cultural factors may
311 cause individuals to withhold or delay the disclosure of geno-
312 mic information to at-risk relatives (Daly et al. 2016; de Geus
313 et al. 2016; Vos et al. 2011). It has been argued that genetic
314 information pushes the boundaries of individual autonomy
315 from pure independence to a more relational approach to fam-
316 ily responsibility (Widdows 2013). Such approaches stress the
317 balance between rights, responsibilities, and the autonomy of
318 individuals dealing with their own genetic information and the
319 way these considerations intertwine with those of a family
320(Dheensa et al. 2016). Patients may also be unsure of the
321responsibilities of the healthcare professionals who have been
322involved in their diagnosis—some patients believe that their
323clinician is responsible for informing their relatives, rather
324than the patient themself (Mesters et al. 2005).
325Understanding the impact of genomic information on in-
326dividual identity The increasing availability of genomic in-
327formation, within and outside the context of the traditional
328healthcare system (i.e., via direct-to-consumer genetic testing
329companies), provides new opportunities for individuals to en-
330gage with this information (O’Riordan 2016). Individuals are
331able now able to have their own genetic data interpreted by all
332kinds of third-party interpretation services, outside of a clini-
333cal context. Healthcare professionals will increasingly being
334challenged by requests from individuals to help interpret ge-
335netic information that was obtained outside a traditional con-
336text. This might put pressure on healthcare systems, as a lot of
337this information might be of limited clinical validity and utility
338and in most of the cases genetic testing was not on medical
339indication (McGuire and Burke 2011).
340Moreover, genomic information opens up new avenues for
341integrating genomic information into individuals’ conceptions
342of “self” (Novas and Rose 2000). A “balancing” of the per-
343ceptions of one’s “genetic side” as compared with one’s “as-
344pects of oneself” also has relevance not only for personal
345identity, but for expectations, concerns, hopes, and decisions
346regarding genetic/genomic information, technologies, and ser-
347vices. Genetic informationmay be perceived as an exceptional
348window into our deep identity or may be seen as just one of
349many sources of information about the “self.” Further research
350is needed to understand the impact of genomic information on
351patients and families both within and outside the healthcare
352system.
353Researchers, research participants, and the general
354public
355Enabling data sharing while respecting ethical safeguards
356In order to facilitate public health research, a diverse group of
357international and national funders of health research agreed to
358promote “greater access to and use of data” in equitable, eth-
359ical, and efficient ways (Walport and Brest 2011). More spe-
360cifically in genetics and genomics, international and national
361policies and guidelines have established general frameworks
362to guide researchers in their data-sharing endeavors (Expert
363Advisory Group on Data Access 2015; Human Genome
364Organisation 1996; National Institutes of Health 2014; The
365Organisation for Economic Cooperation and Development
3662007). Biomedical journals have also increasingly made data
367sharing a condition of publication (Barbui 2016; Barsh et al.
3682015). In order to enable scientific advances, various
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369 publications have argued for the identification and removal of
370 practical, legislative, professional, institutional, and attitudinal
371 obstacles in order to achieve large-scale creation, access, and
372 integration of data with sufficient sustainability (Burn 2016;
373 Majumder et al. 2016; Wilbanks and Friend 2016). Regarding
374 sharing practices to facilitate downstream uses of data, it is
375 important to ensure that the rights of all parties involved
376 (namely members of the general public, research participants,
377 and their families, researchers, and funding bodies) are
378 respected (Williams and Pigeot 2017). Data sharing, and ge-
379 nomic data-intensive research in general, may trigger con-
380 cerns that differ considerably from concerns regarding re-
381 search with human participants, which traditionally tend to
382 be associated with physical risks. In particular, processing
383 sensitive genomic data may raise informational risks for the
384 data subjects, their family members or ethnic groups. Use of
385 genomic data in a discriminatory manner by third parties, such
386 as insurance companies or employers, is a prime example of
387 the unintended consequences of processing genomic data.
388 Consequently, employing a tailored approach to protect the
389 rights of research participants is necessary (Shabani et al.
390 2014). Data-sharing policies should create mechanisms to re-
391 inforce the accountability of the researchers and data users,
392 thereby ensuring that robust procedures are in place to govern
393 data sharing and to respond to data misuses in an adequate
394 manner (Lemke et al. 2010; Trinidad et al. 2010). Policies
395 should endeavor to establish transparent, fair, and objective
396 access and sharing procedures in order to ensure responsible
397 data sharing (Shabani et al. 2015a), and to avoid unintended
398 secondary uses of the data (O’Doherty et al. 2016). At the
399 moment, data-sharing policies are mostly developed within
400 the context of research projects by funders (e.g., NIH,
401 Wellcome Trust) but are often not harmonized across projects
402 and have a limited outreach (Budin-Ljøsne et al. 2014). For
403 instance, they often do not provide guidance on how data
404 produced within a project should be governed after project
405 completion (Bobrow 2015). Furthermore, data sharing for
406 clinical data is needed for optimal interpretation of variants
407 (Hayden 2012).
408 Importantly, sharing individual-level genomic data also
409 fuels concerns regarding the privacy of data subjects
410 (Rothstein 2010). Privacy breaches resulting from re-
411 identification of data could lead to harm for individuals and
412 undermine public trust on the robustness of the data protection
413 measures adopted by research institutions. Furthermore, while
414 stand-alone anonymized genomic information is currently dif-
415 ficult to re-identify, such re-identification is not impossible.
416 That being said, to date, the reported incidence of re-
417 identification of genomic data has been limited, often requir-
418 ing high levels of expertise (Gymrek et al. 2013; Homer et al.
419 2008; Shringarpure and Bustamante 2015). Nevertheless, the
420 evolving potential of genomics and bioinformatics makes the
421 risks of re-identification and/or privacy breaches moving
422targets, thereby requiring ongoing monitoring of the field
423and assessment of the sufficiency of the pertinent legal, ethi-
424cal, and practical safeguards in place. The importance of
425adopting organizational and technical safeguards has been
426highlighted in the recent General Data Protection Regulation
427(GDPR). While GDPR suggests technical measures such as
428pseuonymization as an example of safeguards, it is crucial to
429further elaborate the additional organizational and technical
430measures to safeguard research participants and patients in
431the view of sensitive health and genomic data processing.
432Adapting oversight and governancemechanisms for geno-
433mic research Current models of research governance were
434created at a time when research was often conducted at one
435site, by one team and involved a limited number of partici-
436pants. These days, much research is often multi-sited, interna-
437tional (e.g., research consortia) and organizationally complex
438(Kaye 2011; Kaye and Hawkins 2014). Effective and flexible
439research governance models that are harmonized across juris-
440dictions are required to meet the needs of current research
441approaches. Mechanisms are needed that enable greater trans-
442parency and allow for a greater involvement of research par-
443ticipants (Homer et al. 2008; Kaye et al. 2015a; Williams et al.
4442015). Data access oversight bodies are examples of new gov-
445ernance tools that might be able to ensure appropriate moni-
446toring of secondary research uses of data (Shabani et al.
4472015b). Data access committees could maintain oversight of
448downstream data uses which are not yet known at the time of
449data and sample collection. It is expected that oversight bodies
450play a key part in reassuring research participants that their
451data is in safe hands and being used in ways that benefit
452science and society or are consistent with the consent they
453have given. In doing so, oversight bodies should adopt fair,
454objective, and transparent access arrangements.
455Assessing innovations in research participation The role of
456research participants in genomic research and data sharing is
457evolving (Dove et al. 2012). It has been argued that both
458research participants and researchers would benefit from the
459active involvement of participants in various steps of the re-
460search process, from data collection to the management of
461data access (Erlich et al. 2014), and also obtaining their input
462when developing research policies (Pomey et al. 2015). Some
463have argued that by using the potential of various online plat-
464forms, individuals’ ongoing interactions with researchers, re-
465search institutions and other participants would be facilitated.
466DNA.LAND, Free The Data, and Patients Like Me exemplify
467initiatives that enable a broad scope of research participation
468by individuals, including sharing personal genomic and
469health-related data. The potential challenges to research ethics
470principles of adopting such approaches require further explo-
471ration (Shabani and Borry 2015). Individuals should have suf-
472ficient understanding of the research procedure and the
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473 associated risks and benefits to ensure informed decisionmak-
474 ing (Pereira et al. 2014). In particular, concerns exist with
475 regard to the sharing of genomic data with biotech and phar-
476 maceutical companies (Roberts et al. 2017). Questions also
477 exist with regard to the transparency of such data sharing,
478 the appropriateness of used informed consent and the potential
479 lack of ethics approval (Niemiec and Howard 2016).
480 Assessing innovations at the level of informed consent
481 (Mascalzoni et al. 2008) Ideally, consent for healthcare pro-
482 cedures is a dynamic process, with an emphasis on disclosure
483 of relevant information to the client, and then assessing the
484 client’s understanding of the information and their ability to
485 communicate their consent (Appelbaum 2007). In practice,
486 consent for genetic testing often involves a punctual/one off
487 process whereby experts provide information to participants,
488 who then sign a paper-based consent form. However, this
489 approach may be insufficient to inform research participants
490 about the scope of research and the associated risks and ben-
491 efits (Hayden 2012). The perceived shortcomings of this ap-
492 proach have led some to conclude that the current consent
493 process, including the forms, are insufficient, and thus
494 adopting alternative approaches appears inevitable (Hayden
495 2012). Alternative models, such as dynamic consent, have
496 been suggested in order to introduce more flexibility to the
497 consent process (Budin-Ljøsne et al. 2017; Kaye et al. 2015b).
498 While these new consent models have potentially beneficial
499 aspects in addition to obtaining andmaintaining valid consent,
500 such as increased participant engagement (Teare et al. 2015),
501 they still need further research and analysis.
502 Genomics, society, and its values
503 Minimizing and avoiding negative disruptive uses and im-
504 pact of genetic information Little is known about how indi-
505 viduals or societies at large deal with genomic testing infor-
506 mation or how such information impacts social relations (for
507 example, when information is found about predispositions to
508 stigmatizing diseases such as mental disorders (Gershon and
509 Alliey-Rodriguez 2013) or cancer (Tercyak et al. 2013)).
510 Stigmatization based on genomic information, whether it is
511 based on genomic markers for ethnicity or disease, is a con-
512 cern and steps should be taken to ensure that genomic infor-
513 mation is not disruptive at either the familial or societal levels.
514 Genomic information may be used to discriminate against
515 individuals and their families (for example, in the work place
516 or by insurers) on the basis of their genetic profile/genetic risk
517 predisposition. Cases already exist of discrimination based on
518 information produced through the genetic screening of new-
519 borns (Levenson 2016). Some groups, such as ethnic minori-
520 ties (Joly et al. 2014) and future generations/offspring, may be
521 particularly exposed to genetic discrimination. Indigenous
522peoples can also be exposed to genetic stigma and discrimi-
523nation, and mechanisms to mitigate this need to be developed
524(Arias et al. 2016). Finally, human rights infringements can
525occur in countries which aim to collect the DNA from all of
526their citizens in order to develop forensic databases (as exem-
527plified by the recent case of Kuwait) (O’Doherty et al. 2016;
528Thielking 2016).
529Equity and fairness in service provision and access to ben-
530efits of genomic technologies Recent developments have re-
531sulted in an increase in the number of genetic tests available
532(GeneTests 2016) and a decrease in the price of genome se-
533quencing. Therefore, the number of people who could access
534and potentially benefit from genetic testing is larger than ever
535(Rehm 2017). However, few studies describe to what extent
536the population for whom clinical benefit can be achieved is
537adequately served. There is a possibility that only those people
538who can personally afford the testing, or who are included in
539research projects, would undergo testing, such as a relatively
540high proportion of highly educated people in affluent coun-
541tries. This raises serious ethical issues around the inequality of
542access to genomic healthcare. Authors who describe the re-
543duced cost of sequencing, such as the $1000 genome, rarely
544mention the additional human resource costs involved in in-
545terpretation and downstream clinical care (Morrison et al.
5462014). Given the financial constraints in healthcare systems,
547if not all services/technologies can be covered, criteria should
548be developed to determine which genetic services or genetic
549testing technologies should be funded from public budgets
550(Severin et al. 2015). Prioritization of genetic testing should
551be based on considerations of medical benefit, health need,
552empowering life-time decision making, and costs (Severin
553et al. 2015). However, the demands of fairness and equity
554(as with concerns over inequalities of access) may be more
555complicated and in need of more carefully nuanced responses
556than may initially appear. There is a general underlying con-
557cern that is related to the idea that should differential access to
558genetic technologies be allowed for those who are able to pay,
559it would give rise to new forms of unfairness and unjust in-
560equalities—indeed, a key concern for many is how it would
561affect the central notion of equality of opportunity in society.
562Nevertheless, simply restricting differential access may be
563problematic from the point of view of overall utility (leveling
564down where not accessible to all) and requiring equal or uni-
565versal access (or even reasonable approximations of either in
566the near term) may not be feasible when we are talking about a
567highly expensive (and to many extents limited) good that has
568to be weighed against other priorities in any public budget
569(e.g., with regard to education, general healthcare, water treat-
570ment, infrastructure, housing, etc.) (Farrelly 2007).
571Conversely, while Crozier and Hajzler (2010) note that many
572would view market forces as conflicting with the public good,
573they also highlight the role of such forces in promoting this
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574 good by widening access to the technologies in question. The
575 market, they suggest, would advance the access by those less
576 well-off to genetic technology through the market stimulus
577 achieved by the wealthy gaining such access at an earlier point
578 (Crozier and Hajzler 2010). An ideal egalitarian scenario that
579 would not give proper scope to the potential role of the private
580 sector and of private incentives (usually via the notion of
581 “profit”) could be an overtly romanticized idea (Farrelly
582 2007). Given the feasibility constraints of most western soci-
583 eties, with limited budgets and a costly technology (while
584 reducing in cost, it is still relatively costly, especially taking
585 into account all steps involved), including a role for the private
586 sector, via a regulatory framework that permits some
587 innovation-friendly incentive-based inequalities in access,
588 may be the best approximation of long-term fairness and
589 equity.
590 Linking genomic data to other data sources A particular
591 concern about data use in genomics refers to the continuously
592 developing possibilities of interpreting and understanding ge-
593 nomic information. Given the exponential growth in data stor-
594 age capacities and computational infrastructure, the integra-
595 tion of genomic data into the vast amounts of existing data will
596 provide additional opportunities to capture the significance of
597 genomics for improvement of health. Data brokers, such as
598 Axicom, and data holders, such as Google and Facebook,
599 collect personal information about consumers, and then com-
600 bine and analyze said data to make inferences about them,
601 including potentially sensitive inferences. This may infringe
602 the privacy of individuals and expose them to significant risks
603 (for instance, because data brokers often store data indefinite-
604 ly) (Federal Trade Commission 2014). Therefore, adopting
605 adequate legal safeguards for privacy of the individuals and
606 addressing pertinent issues, such as intellectual property and
607 access by the third parties, will be of paramount importance.
608 Similarly, data brokers are paying attention to the potential
609 uses of genomic data. The current largest data holders would
610 be able to connect an analysis of genomic data to an extraor-
611 dinarily fine-grained and comprehensive set of behavioral and
612 social information arising from their pervasive services.
613 Drawing on such a vast repository of “life world”-related in-
614 formation may allow previously unprecedented opportunities
615 for the analysis and contextualization of genomic information.
616 This will create opportunities for new knowledge and insight,
617 as well as significant potential for abuse. One particular con-
618 cern in this context is the impact of the availability of such
619 information on data privacy. As vast quantities and types of
620 data, including face and fingerprint recognition, keyboard typ-
621 ing or other web surfing habits, consumer characteristics, and
622 genome predictions, are available to a large number of com-
623 mercial stakeholders, these stakeholders can cross link distant
624 data sources (Wjst 2010). Genomic information is likely to
625 become part of that integrated picture, especially if it is shared
626via the Internet and outside protected spaces. Accordingly,
627genetic privacy is becoming increasingly less likely in the
628long-term. A general issue that this raises concerns the conse-
629quences of a shift in power whereby those who are gathering,
630cross-linking and analyzing the digital footprints of individ-
631uals may have more knowledge about the individual than the
632individual herself (Lupton 2015). While the unprecedented
633availability of this amount of data may be a type of “holy
634grail” for data researchers, it poses many ethical challenges
635that extend beyond the practical/technical challenges of the
636development of hardware capable of dealing with the amount
637of data. In addition, the increasing use of algorithms in
638healthcare setting raise questions about accountability of the
639users and potential risks for the data subjects (Mittelstadt and
640Floridi 2016).
641Industry, governments, and citizens
642Balancing public and private interests The past decade has
643witnessed the rapid development of genomics research.
644Industry has played an important role in both the development
645of genomic research and the translation from research to clin-
646ical practice (Zerhouni et al. 2007). Policy makers have en-
647dorsed collaborations between public and private partners
648with the goal of stimulating innovation and the economy, cre-
649ating jobs, and achieving a faster implementation of new tech-
650nologies (Department of Health UK 2013). However, the in-
651teraction between public and private actors is also associated
652with ethical and social challenges. Finding balances between
653public and private interests has been a long lasting difficulty in
654human genetics (Contreras 2014). Symbolic of this was the
655competition between the public consortium of the
656International Human Genome Project and the private compa-
657ny Celera Genomics, to see which could sequence the human
658genome first. Discussions have also revolved around genetic
659disease patents, such as the Association for Molecular
660Pathology vs. Myriad Genetics (2013) and the Greenberg v.
661Miami Children’s Hospital Research Institute cases (Sterckx
662and Cockbain 2016). Furthermore, various debates have de-
663veloped about the access of commercial companies to
664population-based biobanks, such as deCODE genetics in
665Iceland (Árnason and Andersen 2013). In December 2016,
666academic institutions met in court to decide on gene editing
667patents, potentially worth billions (Potenza 2016). Although
668these various cases highlight different problems, they all illus-
669trate the challenge of finding a balance between, on the one
670hand, stimulating research and innovation, and, on the other
671hand, promoting ethical values such as trustworthiness, re-
672spect for autonomy, transparency, and respect for confidenti-
673ality and privacy. Similarly, involvement of industry raises
674concerns about how to reconcile private and public interests
675in an adequate manner. For many examples in medicine (e.g.,
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676 medications) it is clear that without industry involvement,
677 diagnostic and therapeutic advances would not have been
678 translated as quickly into clinical practice (Hawkins et al.
679 2009). However, the involvement of industry and commer-
680 cialization brings challenges relating to trust (Chalmers and
681 Nicol 2004), knowledge exlusion, trade secrets, and monopo-
682 lies (Hong and Walsh 2009; Mitchell et al. 2011), intellectual
683 property, conflict of interests, data sharing, informed consent,
684 privacy, and confidentiality. Policy developments in the do-
685 main of human genetics should aim to maximize public ben-
686 efit while allowing a level of intellectual property protection
687 that is reasonably necessary to achieve that benefit. It should
688 also be noted that while the inclusion of private interests and
689 forms of incentive can be beneficial for fostering innovation
690 and, thereby, widening access (albeit unequally), the
691 balancing of such public and private interests can have a neg-
692 ative effect on levels of self-interest and altrustic motivations
693 in society more generally and so would also be a reason for
694 limiting any unqualified embrace of the private sector as a
695 reliable means of promoting access for all in the longer term
696 (Feeney 2012).
697 Defining appropriate policies with regard to direct-to-
698 consumer genetic testing For over a decade, genetic testing
699 companies have been marketing and selling genetic tests di-
700 rectly to consumers. This offer happens via the Internet, and
701 often bypasses the traditional healthcare system and any
702 healthcare professional involvement; due to these reasons,
703 and more, DTC companies have been a source of controversy
704 in academic and policy debates (Howard and Borry 2012).
705 While the size of the DTC genetic testing market remains
706 largely unknown (except for 23 and me), it is probably rela-
707 tively small. On the one hand, many companies that once sold
708 DTC genetic tests have left the market. Various companies
709 now collaborate with physicians and the traditional healthcare
710 system, and have distanced themselves from a consumer-
711 driven access model. On the other hand, as genetic testing
712 has become much more affordable over the years and genetic
713 testing has become more socially acceptable, various compa-
714 nies have remained in the field. A review of public and orga-
715 nizational policies on DTC indicated there was no uniform
716 approach, with some professional organizations warning of
717 harms and others supporting autonomous choice (Skirton
718 et al. 2012). Although a new In Vitro Diagnostics (IVD)
719 Regulation was voted at the European level and will come in
720 to force in 2022, for regulators at the national level, the issue
721 of DTC genetic testing will certainly remain on the agenda for
722 the coming years. (For a more elaborated discussion of the
723 regulatory aspects related to the provision of genetic tests,
724 please consult following article (Q5 Kalokairinou et al. 2017) in
725 this thematic issue) A first important policy question is the
726 extent to which regulators want to intervene in the provision
727 of genetic tests. Some have argued that “the embedding of
728genetic testing in a healthcare setting can ensure a context
729where due emphasis is being provided on the individualized
730medical supervision of patients, the presence of pre-test and
731post-test counseling, psychological evaluation and follow-up
732if appropriate and quality assurance of the tests performed”
733(Ayme et al. 2013). However, there are discussions regarding
734whether this should also apply to categories of tests that are
735labeled as “informational” or “recreational” or that do not
736offer any assessment of disease risk (Caulfield et al. 2015).
737Second, legislators can also impact the extent to which genetic
738tests are occurring within the scope of the healthcare system.
739Some countries have developed legislation that does not allow
740for direct access to genomic information, and imposes canali-
741zation of genetic tests through medical doctors or healthcare
742professionals (Kalokairinou et al. 2015). Third, various com-
743mentators have proposed a role for regulatory bodies in im-
744posing and enforcing “truth in advertising” requirements in
745order to respond to the concerns relating to inaccurate infor-
746mation provision and subsequent consumer misunderstanding
747concerning the validity and utility of genomic information
748provided (ter Meulen et al. 2012). Fourth, the development
749of educational interventions targeted towards healthcare pro-
750fessionals and the general public in order to inform these
751groups about the lack of scientific validity and relevance of
752many of these DTC tests, has been suggested (terMeulen et al.
7532012). Finally, any regulation that would be developed to
754manage the DTC genetic testing market would always have
755to deal with the issue of (international) enforcement. It re-
756mains difficult to apply a regulatory control on an internation-
757al market functioning through the Internet.
758Cross-cutting themes
759Maintaining trust Various studies have shown that (public)
760trust is a cornerstone of participation in genomic research
761(Nobile et al. 2013). But trust is also fragile, and efforts need
762to be made at the level of information provision, consent pro-
763cedures, and governance mechanisms in order for research
764participants to develop and maintain trust in research.
765Various studies have consistently found that publics have high
766levels of trust in universities and government research organi-
767zations. However, studies also show that trust in research di-
768minishes if the research is funded by industry (Critchley and
769Nicol 2009). As knowledge of potential commercial access to
770genomic information is known to be a relevant consideration
771in the decision to participate in research, transparency regard-
772ing commercial use is ethically required (Caulfield et al.
7732014). Informed consent is a mechanism that allows individ-
774uals to receive information to enable them to participle in
775research in a voluntary way. However, informed consent
776comes with its limitations and needs to be complemented by
777other governance mechanisms that might address societal
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778 concerns. In order to keep trust in technological innovations, it
779 is also of crucial importance that appropriate safeguards are in
780 place in order to protect individuals from inappropriate dis-
781 crimination and stigmatization based on genetic information,
782 and also human rights more broadly.
783 Evidence building Despite technological progress, there is
784 still a wide gap between the DNA sequence data than can be
785 generated and our ability to both interpret sequence variants
786 and to derive possible health implications from sequence al-
787 terations in genes (Stemerding and Krom 2013). Although,
788 clinical implementation of NGS technologies has proven to
789 be valuable, various challenges remain before routine use of
790 this technology can occur (Caleshu and Ashley 2016;Manolio
791 et al. 2013). These include a lack of evidence and conflicting
792 interpretations of benefit, a lack of institutional and clinical
793 acceptance, and limited access to genomic medicine and test-
794 ing. It also includes a lack of standards for genomic applica-
795 tions such as: integration of genomic results into electronic
796 medical records and clinical decision support; follow-up of
797 genotyped patients; outreach to at-risk family members; con-
798 sent; understanding by patients, clinicians, and public; lack of
799 access to comparison “control” sequence data and banking
800 resources; and lack of research funding and reimbursement.
801 Solutions to these problems are necessary in order to allow
802 successful and responsible implementation into the clinical
803 setting. Various commentators have also described the need
804 for databases that include a comprehensive overview of ge-
805 netic variants and related phenotypic information. This infor-
806 mation should be accessible to various clinical groups world-
807 widewho are involved in interpreting sequence data in clinical
808 care and research. Many groups are currently doing this in
809 isolation, and data sharing would benefit many patients
810 around the world. Policies that reward or require data
811 sharing should be developed (Cook-Deegan et al. 2013).
812 Nevertheless, due attention should be paid to the legal require-
813 ments across jurisdictions that may concern cross-border shar-
814 ing of genomic data. Furthermore, the views of the public
815 need to be taken into account (Bentzen and Svantesson
816 2016; Majumder et al. 2016).
817 Transferring knowledge to stakeholders
818 The full potential of the progress being made in genomics and
819 related fields will not be realized unless the knowledge gen-
820 erated by such endeavors is translated into a usable format and
821 transferred to all relevant stakeholders in society. The fore-
822 most focus should be on how best to inform all relevant stake-
823 holders about the potential benefits and harms regarding
824 accessing their genetic information from different sources,
825 on developing and advertising best practice procedures, and
826 on facilitating access to genetic knowledge in the most
827responsible and ethically acceptable way. As such, education
828must address all aspects of the technologies, including ethical
829issues and scientific validity. Rapid education and training in
830genomics is required for many different practitioners in the
831healthcare setting, from scientists and bioinformaticians car-
832rying out diagnostic tests, to doctors in non-genetic specialties
833who may increasingly order such tests independently of clin-
834ical genetics services, to primary care clinicians such as GPs,
835specialist nurses, and midwives. Each stakeholder group will
836have different educational needs, and training must be prag-
837matic and reflect practical needs for certain information rather
838than an idealistic goal to upskill everyone significantly in all
839aspects of the field.Multi-national coordinated efforts (such as
840the Medgen Project or the Gen-Equip project) will be essential
841moving for forward in assisting with the mainstreaming and
842standardization of genomics into clinical care, as well as im-
843proving the visibility of genetics as a whole in the European
844context.
845Ensuring data security in clinical and research
846setting
847Genetic data is being processed, stored and analyzed on an
848unprecedented scale thanks to decreasing costs; ~ 250,000
849individual human genomes have been sequenced or are in
850progress thus far (Regalado 2014). Even with conservative
851estimates of doubling data quantities every 18months, we will
852probably reach massive scale of data generation within the
853next decade. It is estimated that by 2025 between 1 and 25%
854of the eight billion humans worldwide will have had their
855genome sequenced (Stephens et al. 2015). The emerging pos-
856sibilities for obtaining and storing genomic information and
857making it available to individuals, raise novel challenges with
858regard to the security of storage and processing. In many ju-
859risdictions, genetic information is a type of information that
860receives special protection ( Q6Equal Employment Opportunity
861Commission 2008) and information and communication tech-
862nology (ICT) security measures need to meet those require-
863ments. Platforms that host or analyze genetic information need
864to be equipped against security threats. In particular, the pri-
865vacy of the data subjects, integrity of the databases and avail-
866ability of the data to authorized users should be reinforced.
867Attention needs to be paid not just to the development of a
868secure computing platform, but also to the security of poten-
869tially associated cloud providers, the legal protections cloud
870services enjoy in their respective jurisdictions, and to secure
871and controlled modes of access (Bentzen and Svantesson
8722016). Unfortunately, genome data has a distributed data ar-
873chitecture where data acquisition is still not standardized.
874Instead it involves numerous heterogeneous formats (Costa
8752012) which may raise questions about the data integrity and
876the adequate safeguards against unauthorized data uses
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877 (Knoppers et al. 2011). Moreover, the issues regarding the
878 adequate storage and computational infrastructures in a widely
879 accessible manner should be taken into consideration.
880 (Eisenstein 2015).
881 Conclusion
882 The expanded availability of genetic information is expected
883 to influence the relationship between various parties, includ-
884 ing healthcare professionals, individuals, families, research
885 participants, researchers and industry. We have highlighted
886 the main challenges arising from the availability of such in-
887 formation, and suggested areas for further research. In partic-
888 ular, we have underlined the significance of maintaining trust,
889 building evidence, transferring knowledge to stakeholders,
890 and ensuring data security in clinical and research settings,
891 as the core elements to be respected in light of the expanded
892 availability of genomic data and the identified challenges.
893 The identified challenges with regard to the expanded
894 availability of genomic data require various stakeholders
895 to engage in constructive discussions regarding the best
896 practices for reporting test results, including reporting inci-
897 dental findings and VUS. Given the familial implications of
898 genetic data, it is essential to strike a balance between the
899 rights, responsibilities, and autonomy of individuals deal-
900 ing with their own genetic information, and the way these
901 considerations intertwine with those of a family. Notably, in
902 dealing with genetic data, it is essential to respect social
903 values, such as fairness and justice.
904 Furthermore, developing adequate tools and guidelines in
905 order to assist researchers in sharing genetic data is critical.
906 Informed consent, privacy safeguards and oversight mecha-
907 nisms should be improved in order to adequately address the
908 concerns of individuals relating to data sharing and to ensure
909 the ethical and legal footing of data sharing. Concurrently,
910 educating both professionals and the general public could
911 raise awareness regarding the significance of access to geno-
912 mic data and assist in clarifying the roles and responsibilities
913 of the parties involved.
914 The role of regulatory bodies in regulating various aspects
915 of genetic testing within clinical and research settings is
916 highlighted by this paper. In particular, regulating various as-
917 pects of commercial direct-to-consumer genetic testing, in-
918 cluding advertisement of the products and the responsibilities
919 of healthcare professionals in dealing with the results of such
920 tests, are recognized as matters of concern.
921 The advancements in genomics and bioinformatic technol-
922 ogies urge an ongoing monitoring of the associated chal-
923 lenges, and the adequate addressing of them through robust
924 policies. It is expected that this paper will direct future re-
925 search and provide grounds for potential policy developments
926 if needed.
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